A phase II study (NCT04145115) that aims to ascertain if a combination of Ipi and Nivo increases the tumor response rate, as determined by modified Response Assessment in Neuro-Oncology (RANO) Criteria, in patients with hypermutated histologically confirmed rGBM is currently ongoing (some cases are categorized under astrocytoma, IDH-mutant, WHO grade 4, due to the new WHO 2021 classification). The gene discussed is IDH1; the disease is neoplasm.